Topics

Latest "Arrowhead Pharmaceuticals Inc." News Stories

22:00 EST 27th February 2020 | BioPortfolio

Here are the most relevant search results for "Arrowhead Pharmaceuticals Inc." found in our extensive news archives from over 250 global news sources.

More Information about Arrowhead Pharmaceuticals Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Arrowhead Pharmaceuticals Inc. for you to read. Along with our medical data and news we also list Arrowhead Pharmaceuticals Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Arrowhead Pharmaceuticals Inc. Companies for you to search.

Showing "Arrowhead Pharmaceuticals" News Articles 1–25 of 5,300+

Thursday 27th February 2020

Spectrum Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Pipeline Update

BLA for ROLONTIS® (eflapegrastim) accepted for FDA review - PDUFA date on October 24, 2020 Data from poziotinib Cohort 1 of ZENITH20 accepted for podium presentation on March 18 at 11th Annual Congress on Pulmonary and Respiratory Medicine in Amsterdam Spectrum plans to hold a conference call following the data presentation to review the data and strategy of the program Spectrum Pharmaceuti...


Biotech Report: Evotec (EVT) und MorphoSys (MOR) weiter schwach, Regeneron (REGN) und Arrowhead (ARWR) fester

(shareribs.com) Frankfurt / New York 27.02.2020 - Die Aktienmärkte befinden sich nach wie vor im Krisenmodus. Diesem können sich auch Biotech-Werte nicht entziehen. Im deutschen Handel geht es für ...

BioUtah and the University of Utah’s TVC Announce the Opening of the 2020 Entrepreneur & Investor Life Science Summit, February 28

The 2020 Entrepreneur & Investor Life Science Summit, sponsored by Simpson Thacher, is the premier conference for engaging life sciences executives, entrepreneurs and investors, with a special focus on Utah’s growing medical technology, diagnostics and pharmaceutical sectors BioUtah, Utah’s only trade association dedicated solely to the life sciences, in partnership with the University o...


E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide —Appendix to the Implementation Guide — Backwards and Forwards Compatibility

This document is an appendix to the Implementation Guide (IG) for the ‘International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Electronic Transmission of Individual Case Safety Reports (ICSRs)’.

Acacia Pharma (ACPH) - FDA approves BARHEMSYS for PONV

Edison Investment Research - Pharmaceuticals & healthcare - Acacia Pharma: The US FDA has approved Acacia Pharma’s lead asset, BARHEMSYS (reformulated amisulpride), for the management of post-operative nausea and vomiting (PONV). Rescue treatment for PONV is an unmet need. Acacia plans to launch BARHEMSYS in H220 and management has been slowly building up its US commercial operations. It now...

Alexion Announces Launch of Alexion Charitable Foundation and Calls for Grantees

- Ahead of Rare Disease Day, new support becomes available to the rare community - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of the Alexion Charitable Foundation to provide further support for the rare disease community and for local communities which the company serves. The key components of the Foundation are the Rare Belonging™ and Local Needs Grants focus areas...

Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $133 million and diluted EPS to be $3.62, up from previous guidance for total revenues of approximately $128 million and diluted EPS of $3.45. This increase is due to higher material sales of Ligand’s C...

X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced it will host a conference call and webcast to report its financial results for the fourth quarter and full year ended December 31, 2019 on March 12, 2020 at 8:30 a.m. ET. The conference call can be accessed by di...

Syros to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 5, 2020 to report its fourth quarter and full year 2019 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic)...

Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Platform Trial at Mass General; Zilucoplan selected as one of the first clinical candidates to be evaluated UCB acqu...

Concert Pharmaceuticals Reports 2019 Financial Results and Provides Update on Clinical Programs

CTP-543 Phase 3 Program for Treatment of Alopecia Areata Expected to Begin in 2020 New CTP-543 Patent Covers Pharmaceutical Compositions of CTP-543 and Methods of Treating Alopecia Areata with CTP-543 CTP-692 Phase 2 Topline Results as Adjunctive Treatment for Schizophrenia Expected by Year End 2020 Conference Call Scheduled Today at 8:30 a.m. ET

Pre-clinical Studies Demonstrate CBD’s Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement

In pre-clinical studies, CBD enriched fractions induced anti-liver cancer effect at minute concentrations Expansion of the agreement allows Can-Fite to develop 2 additional clinical indications Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharma

Tonix Pharmaceuticals forms alliance to develop Covid-19 vaccine

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Follow the latest updates of the outbreak on our timeline....Read More... The post Tonix Pharmaceuticals forms alliance to develop Covid-19 vaccine appeared first on Pharmaceutical Technology.

Wednesday 26th February 2020

Global Actinic Solar Keratosis Treatment Market Data Survey Report 20152025 [Published by HeyReport] Prices from USD $1275

SummaryThe global Actinic Solar Keratosis Treatment market will reach xxx Million USD in 2020 with CAGR xx% 20202025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers profile, products services, sales data of businessGlobal market size by Major EndUseGlobal market size by Major TypeKey manufacturers ...

Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

Clinician with deep experience in DMD drug development (ex-Sarepta Therapeutics Director) On the ground presence in the US to accelerate development activities Initial focus on engagement with Key Opinion Leaders and DMD Advocacy Groups Antisense Therapeutics Limited (ASX:ANP) is pleased to advise of the appointment of Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinica...

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020

DEER PARK, Ill., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, March 5, 2020. Management will host a conference call and live audio webcast to ...

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a  product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial resul...

Amphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mL

RANCHO CUCAMONGA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP, 8.4%, 50mEq/50mL (1mEq/mL) Single-Dose Prefilled Syringe. This supplement is for manufacturing the produ...

EyePoint Pharmaceuticals Announces Fourth Quarter and Full-Year 2019 Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fourth quarter and full-year ended December 31, 2019 on Thursday, March 5, 2020. Management will host a conference call to review the results at 8:30 AM ET on ...

Avadel Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results on March 12th

DUBLIN, Ireland, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 12, 20...

Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020

CORAL GABLES, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its support for Rare Disease Day 2020. Rare Disease Day, observed on Fe...

Innovation Pharmaceuticals to Ship Brilacidin to U.S. Regional Biocontainment Laboratory for Research Against Coronavirus COVID-19

WAKEFIELD, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company signed a Material Transfer Agreement (MTA) with one of the country’s 12 Regional Biocontainment Labs (RBLs) to research its lead defensin mimetic drug candidate, Brilacidin, as a potential novel coronavir...

Arrowhead Pharmaceuticals: Pushing the Boundaries of Gene Silencing

Christopher Anzalone, Arrowhead’s chief executive officer, took time to speak with BioSpace about the company’s large pipeline and why they’re so excited about 2020.

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

Positive Top-line Results Announced from Head-to-Head Phase 3 PEGASUS Trial of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)Completion of Enrollment in Phase 3 PRINCE Trial in Treatment-Naïve PNH Patients Expected in First Half of 2020 Full Enrollment of Two Phase 3 Trials in Geographic Atrophy Expected in First Half of 2020Cash Pos...

Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group

PETALUMA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin and wound conditions, is pleased to announce that it successfully closed on an asset purchase agreement for certain woun...


Quick Search

News Quicklinks